IRCT20090429001859N11招募中Unknown
Studying the Effects of Pyridostigmine on Dysphagia in Patients With Multiple Sclerosis: a Randomized Triple-Blind Placebo-Controlled Clinical Trial
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •A diagnosis of multiple sclerosis is made by a neurologist specialized in multiple sclerosis, based on the 2017 McDonald criteria, and the patient is receiving treatment for multiple sclerosis.
- •After explaining the goals and methods of the study and all the sections of the informed consent form, the patient is willing towards participation and cooperation.
- •The patient has a DYMUS score of at least 3, based on the persian version of the questionnaire.
排除标准
- •Any comorbidity due to previous neurological disorders, e.g. previous cerebrovascular accidents.
- •Other neurological disorders
- •A history of relapse (if MS type is relapsing-remitting) in the previous 3 months.
- •An Expanded Disability Status Scale (EDSS) score above 7.5.
- •Currently being under treatment with pyridostigmine for any reasons.
- •A history of hypersensitivity to anticholinesterase inhibitors or any of the compounds found in our placebo.
- •The patient has mechanical obstruction in intestinal or urinary tract.
- •The patient is currently pregnant or breastfeeding.
- •Dysphagia caused by other disorders than MS.
- •Having a decision to start any other treatment for dysphagia in time of the study, or having started in the last 3 months.
研究者
相似试验
招募中
3 期
Investigating the effect of pyridostigmine in individuals with poor ovarian responseIRCT20100518003950N8Tehran University of Medical Sciences110
招募中
3 期
Effect of pyridostigmine in stroke-related dysphagiaIRCT20230520058232N1Sanandaj University of Medical Sciences60
已完成
3 期
the effect of oral pyridostigmine on ileus after abdominal surgerypostoperative ileus (poi).Other postprocedural complications and disorders of digestive systemK91.89IRCT20180123038484N1Zahedan University of Medical Sciences40
招募中
1 期
Improving symptomatic treatment with pyridostigmine and amifampridine in patients with myasthenia gravisMedDRA version: 24.0Level: LLTClassification code 10085562Term: AChR myasthenia gravisSystem Organ Class: 100000004852Myasthenia GravisEUCTR2021-004110-20-NLeiden University Medical Center24
招募中
3 期
Improving symptomatic treatment with pyridostigmine and amifampridine: a randomized double-blinded, placebo controlled crossover trial in patients with myasthenia gravis (IMPACT-MG)Myasthenia GravisNL-OMON54093eids Universitair Medisch Centrum24